Federico Cappuzzo
Rome, 00144, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 254 publications
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
Journal: JAMA oncology
Published: June 04, 2026
Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].
Journal: Experimental and molecular pathology
Published: May 28, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.
Journal: JAMA oncology
Published: April 30, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 17, 2026
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 20, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.
Journal: Cancer treatment reviews
Published: March 06, 2026
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 09, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.
Journal: Experimental and molecular pathology
Published: January 26, 2026
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.
Journal: Clinical lung cancer
Published: January 11, 2026
Last Updated: 09/26/2026